ALLO Allogene Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLO

Price (delayed)

$2.53

Market cap

$425.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.23

Enterprise value

$436.3M

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
ALLO's quick ratio is up by 38% since the previous quarter and by 10% year-on-year
The EPS has grown by 9% from the previous quarter
The net income has decreased by 6% YoY but it has increased by 6% QoQ
The gross profit is down by 25% year-on-year and by 3.1% since the previous quarter
ALLO's revenue is down by 25% year-on-year and by 3.1% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allogene.com
Peers: OMGA

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
168.28M
Market cap
$425.74M
Enterprise value
$436.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
2,280.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,345.72
Earnings
Revenue
$186,000
EBIT
-$332.86M
EBITDA
-$319.07M
Free cash flow
-$249.15M
Per share
EPS
-$2.23
Free cash flow per share
-$1.49
Book value per share
$3.48
Revenue per share
$0
TBVPS
$4.25
Balance sheet
Total assets
$712.33M
Total liabilities
$129.22M
Debt
$90.1M
Equity
$583.1M
Working capital
$435.82M
Liquidity
Debt to equity
0.15
Current ratio
12.58
Quick ratio
12.64
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-171,540.3%
Gross margin
100%
Net margin
-178,954.3%
Operating margin
-182,224.2%
Efficiency
Return on assets
-43.7%
Return on equity
-54%
Return on invested capital
-48%
Return on capital employed
-49.3%
Return on sales
-178,954.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
7.66%
1 week
-10.92%
1 month
-10.6%
1 year
-73%
YTD
-59.78%
QTD
-20.19%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$186,000
Gross profit
$186,000
Operating income
-$338.94M
Net income
-$332.86M
Gross margin
100%
Net margin
-178,954.3%
The operating margin has declined by 44% year-on-year but it has increased by 2.4% since the previous quarter
Allogene Therapeutics's net margin has decreased by 41% YoY but it has increased by 3.1% from the previous quarter
The gross profit is down by 25% year-on-year and by 3.1% since the previous quarter
ALLO's revenue is down by 25% year-on-year and by 3.1% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
0.73
P/S
2,280.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,345.72
The EPS has grown by 9% from the previous quarter
ALLO's price to book (P/B) is 79% less than its 5-year quarterly average of 3.3 and 43% less than its last 4 quarters average of 1.2
Allogene Therapeutics's equity has decreased by 21% YoY and by 6% QoQ
The stock's price to sales (P/S) is 37% less than its last 4 quarters average of 3353.6
ALLO's revenue is down by 25% year-on-year and by 3.1% since the previous quarter

Efficiency

How efficient is Allogene Therapeutics business performance
The return on equity has declined by 43% year-on-year
The ROS has contracted by 41% YoY but it has grown by 3.1% from the previous quarter
The return on assets has declined by 34% year-on-year
ALLO's return on invested capital is down by 33% year-on-year

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's quick ratio is up by 38% since the previous quarter and by 10% year-on-year
ALLO's current ratio is up by 37% from the previous quarter and by 8% YoY
Allogene Therapeutics's debt is 85% less than its equity
Allogene Therapeutics's equity has decreased by 21% YoY and by 6% QoQ
The company's debt to equity rose by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.